
The MODA Platform is a GMP-compliant paperless manufacturing and QC suite (MODA-EM, MODA-ES, MODA eLogs) historically sold by Lonza Bioscience; a discrete "MODA-APQR" SKU is not publicly catalogued, and StarLIMS acquired the platform from Lonza, with the acquisition completed in May 2026 (announced 2026-03-25). Bio-Rad is not the vendor of record.
The MODA Platform is positioned for pharma, biotech, cell & gene therapy, and CDMO organizations as an on-premises / privately-hosted, GMP-compliant suite of paperless manufacturing and QC execution modules. Three publicly catalogued modules: MODA-EM (environmental monitoring / QC microbiology), MODA-ES (electronic batch records / MES, with Weigh & Dispense sub-module), and MODA eLogs.
An Annual Product Quality Review function is not a discrete, separately-licensed module within the public MODA product family; APQR-relevant data aggregation, trending, and reporting are described as analytics/visualization capabilities of MODA-EM and MODA-ES rather than as a named SKU. MODA originated as MODA Technology Partners (Wayne, PA), acquired by Lonza in 2010. Lonza and StarLIMS (Turn/River Capital portfolio) announced an acquisition agreement on 2026-03-25; StarLIMS completed the acquisition of the MODA Platform from Lonza in May 2026.
Bio-Rad Laboratories was not party to the transaction and is not a vendor of MODA.
MODA is purpose-built for pharma GMP manufacturing and QC. Modules: MODA-EM (QC micro), MODA-ES (eBR/MES), MODA eLogs, Weigh & Dispense. No separately marketed APQR edition.
Predominantly on-premises / customer-hosted deployment, consistent with case studies (Lonza Walkersville, BioMarin, Adaptimmune, Nephron, VMIC, KBI Biopharma). No public multi-tenant SaaS positioning; StarLIMS post-acquisition product positioning not yet published. MODA-EM uses wireless technology with proprietary offline capabilities; MODA-FDC historically shipped with rugged tablets, barcode scanners, and printers.
Documented integration: LabVantage LIMS bi-directional interface. Other named connectors (SAP, Oracle, Veeva Vault, Werum PAS-X, Rockwell PharmaSuite, Siemens Opcenter), SDK details, SSO providers, and data residency options are not publicly documented.
Pricing is opaque. Modular design implies module-based licensing ("Choose the module that's right for you now... by adding additional modules when needed"). Vendor marketing repeatedly emphasizes "lower total cost of ownership" without listing prices. Demo requests via "Request a demo" forms on lonza.com/moda. No public free trial. Reported deal sizes, minimum commitments, setup fees, and validation-support fees are not disclosed.
Specific timelines are not publicly disclosed. Lonza describes "easy and rapid deployment" and a Nephron Pharmaceuticals case study referencing an "accelerated timeframe" without disclosing the duration. Implementation, validation support, training, and change management bundling is not publicly itemized; NNIT is documented as a long-standing implementation, validation, and recipe-configuration partner. Migration tooling and named legacy migrators are not documented.
PharmaSpotter assessment from published vendor and third-party sources. No user reviews are on file for this product.
Vendor-published testimonials emphasize replacement of paper-based batch release with rapid digital release (Exela Pharma Sciences) and consolidation of QC micro on MODA-EM without a separate LIMS (Nikon Cell innovation Co.). Pitch differentiator is origin inside Lonza's own CDMO operations — "built by an operating CDMO for CDMO-like workflows."
No public negative-review content located. The following APQR-relevant capabilities are not publicly documented for MODA: statistical process control, batch genealogy, deviation/CAPA/change-control roll-up, OOS/OOT reporting, pre-built 211.180(e) and EU GMP §1.10 templates, and multi-product/multi-site consolidation. StarLIMS completed its acquisition of the platform from Lonza in May 2026, and the post-acquisition roadmap is not published.
Share your experience with MODA Platform (STARLIMS; formerly Lonza) - positioned here as MODA-APQR anonymously. Your insights help pharmaceutical professionals make better software decisions.
Contribute Anonymous FeedbackPublicly disclosed pharmaceutical and biotech organizations
Jump to section